Zenosense and Sgenia Group are together
focused on developing an advanced MRSA sensor. Both companies are involved in
the design and creation of a cost-effective methicillin-resistant
staphylococcus aureus (MRSA) detection system which is integral in fighting off
what some have referred to as a multi-billion dollar problem. Headquartered in
Madrid, Sgenia Group has established Zenon Biosystem, a subsidiary contracted
to develop the MRSA device for Zenosense. It is anticipated that the product
will appeal to distributor channels and end users due to the rising need for an
economical detection solution.
MRSA (Methicillin-resistant Staphylococcus
aureus) is a result of a strain of staph bacteria that resists the antibiotics
used to treat every day staph infections. MRSA infections commonly occur in
people who have been in hospitals or other health care environments. These
locales include nursing homes and dialysis centers. In these settings the
infection is known as health care-associated MRSA (HA-MRSA). HA-MRSA infections
typically arise by way of invasive procedures such as intravenous tubing,
surgeries and artificial joints.
A variation of the infection has been known
to occur among healthy people. Usually surfacing as a boil on the skin, this
type of outbreak is referred to as community-associated MRSA (CA-MRSA) and is
spread through skin-to-skin contact. Populations at risk are groups such as
child care workers, high school wrestlers, and people with lifestyles where
population totals are dense.
A device referred to as an ‘electronic nose’
currently exists to detect bacteria from cultures. Unfortunately, the device is
bulky and expensive to install on larger scales. There is no cost-effective
system available for detecting MRSA infection early in the patient or in
environments where it is known to be contracted. The company plans to install a
detector on a special sensor developed by Sgenia. After installation, the
device detects the Volatile Organic Compounds (VOCs) signature emitted by MRSA.
The MRSA VOC notification is emitted when the bacteria has infected and
expressed itself as a disease in the patient. Most notably, the infection can
be detected before to the patient develops symptoms, which subsequently aids in
earlier intervention.
For more information, visit www.zenosense.net
About
QualityStocks
QualityStocks is committed to connecting
subscribers with companies that have huge potential to succeed in the short and
long-term future. We offer several ways for investors to find, evaluate, and
learn more about investing in these companies.
Sign up for “The QualityStocks Daily
Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks
website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment